Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I
4 affiliations
- 1Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany
- 2Osteology/Clinical Trial Unit, University of Würzburg, Würzburg, Germany
- 3Department of Musculoskeletal Tissue Regeneration, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, Würzburg, Germany
- 4Julius-von-Sachs-Institute of Biosciences, Biocenter, Pharmaceutical Biology, University of Würzburg, Würzburg, Germany
Abstract
Introduction: Osteoporosis is a highly prevalent health concern both in terms of disability to an individual and costs to society. While antiresorptive drugs are the standard treatment, nutritional supplementation may offer additional advantages, particularly in the pre-therapeutic stage of osteopenia or clinically stable osteoporosis. The French maritime pine bark extract Pycnogenol® exhibits antioxidant and anti-inflammatory properties, but its influence on bone turnover has not been investigated in humans yet.
Methods: In this randomized, placebo-controlled, double-blind clinical trial, 67 women received either Pycnogenol® (100 mg twice daily; n = 33) or placebo (n = 34) during a 3-month placebo-controlled phase, followed by a 3-month active-treatment extension, in which all participants took Pycnogenol®. The primary endpoint included changes in the bone resorption marker C-terminal telopeptide of type I collagen (CTX-1) and bone formation marker procollagen type I N propeptide (P1NP) in serum. Secondary endpoints comprised other bone turnover markers (N-terminal telopeptide of type I collagen, NTX-1; tartrate-resistant acid phosphatase 5b, TRAP5b; bone sialoprotein, BSP), an inflammatory marker (interleukin-6, IL-6), the microbial metabolite 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (M1), and in vitro differentiation experiments with human mesenchymal stromal cells (hMSCs).
Results: Within the Pycnogenol® group, serum CTX-1 levels were significantly reduced after both three (p = 0.0327) and 6 months (p = 0.0227) compared to baseline, while no between-group differences were observed at any visit. No significant changes were observed in P1NP concentrations. Additionally, a significant reduction from baseline was observed for NTX-1 serum levels in the Pycnogenol® group at the end of the active-treatment extension (p = 0.0100). Salivary M1 concentrations were significantly higher following 3 months of Pycnogenol® supplementation compared to placebo (p = 0.0289) and showed an inverse association with CTX-1 concentrations (r = −0.216, p = 0.013, n = 131).
Conclusion: Dietary supplementation with Pycnogenol® was associated with reductions in key bone resorption markers within the treatment group, while metabolite concentrations in saliva increased. Furthermore, Pycnogenol® components enhanced the osteogenic differentiation of hMSCs in vitro. These findings suggest a potential protective effect of Pycnogenol® on bone turnover in osteopenia and clinically stable osteoporosis.
Clinical trial registration: https://drks.de/search/de/trial/DRKS00026630, DRKS00026630.
Related
- Quality of life and safety of a dietary intervention with French maritime pine bark extract (Pycnogenol®) in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part II
- Influence of dietary supplementation with French maritime pine bark extract (Pycnogenol®) on endothelial glycocalyx structures in a dynamic cell culture model
- Efficacy of a weighted-vest aerobic dance intervention for enhancing lower extremity strength and mobility in older adults: a randomized controlled trial
- Culturally adapted home-based intervention to improve child’s development in Arab toddlers in Israel: study protocol for a randomized controlled trial
- Whole-course care intervention for patients with spinal cord injury: study protocol for a randomized controlled trial
BibTeX
@article{scherg2026impact,
title = {{Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I}},
author = {Christian Scherg and Franca Genest and Jonas Maghary and Lothar Seefried and Denitsa Docheva and Markus Krischke and Petra Högger},
journal = {Frontiers in Nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1923949},
url = {https://doi.org/10.3389/fnut.2026.1923949},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I
AU - Christian Scherg
AU - Franca Genest
AU - Jonas Maghary
AU - Lothar Seefried
AU - Denitsa Docheva
AU - Markus Krischke
AU - Petra Högger
PY - 2026
DA - 2026/10/12
JO - Frontiers in Nutrition
DO - 10.3389/fnut.2026.1923949
UR - https://doi.org/10.3389/fnut.2026.1923949
AB - Introduction: Osteoporosis is a highly prevalent health concern both in terms of disability to an individual and costs to society. While antiresorptive drugs are the standard treatment, nutritional supplementation may offer additional advantages, particularly in the pre-therapeutic stage of osteopenia or clinically stable osteoporosis. The French maritime pine bark extract Pycnogenol® exhibits antioxidant and anti-inflammatory properties, but its influence on bone turnover has not been investigated in humans yet. Methods: In this randomized, placebo-controlled, double-blind clinical trial, 67 women received either Pycnogenol® (100 mg twice daily; n = 33) or placebo (n = 34) during a 3-month placebo-controlled phase, followed by a 3-month active-treatment extension, in which all participants took Pycnogenol®. The primary endpoint included changes in the bone resorption marker C-terminal telopeptide of type I collagen (CTX-1) and bone formation marker procollagen type I N propeptide (P1NP) in serum. Secondary endpoints comprised other bone turnover markers (N-terminal telopeptide of type I collagen, NTX-1; tartrate-resistant acid phosphatase 5b, TRAP5b; bone sialoprotein, BSP), an inflammatory marker (interleukin-6, IL-6), the microbial metabolite 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (M1), and in vitro differentiation experiments with human mesenchymal stromal cells (hMSCs). Results: Within the Pycnogenol® group, serum CTX-1 levels were significantly reduced after both three (p = 0.0327) and 6 months (p = 0.0227) compared to baseline, while no between-group differences were observed at any visit. No significant changes were observed in P1NP concentrations. Additionally, a significant reduction from baseline was observed for NTX-1 serum levels in the Pycnogenol® group at the end of the active-treatment extension (p = 0.0100). Salivary M1 concentrations were significantly higher following 3 months of Pycnogenol® supplementation compared to placebo (p = 0.0289) and showed an inverse association with CTX-1 concentrations (r = −0.216, p = 0.013, n = 131). Conclusion: Dietary supplementation with Pycnogenol® was associated with reductions in key bone resorption markers within the treatment group, while metabolite concentrations in saliva increased. Furthermore, Pycnogenol® components enhanced the osteogenic differentiation of hMSCs in vitro. These findings suggest a potential protective effect of Pycnogenol® on bone turnover in osteopenia and clinically stable osteoporosis. Clinical trial registration: https://drks.de/search/de/trial/DRKS00026630, DRKS00026630.
SN - 2296-861X
ER -